Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vabomere vs Best Available Therapy for CRE Infections (TANGO II)
NCT02168946Phase 3Completed
- Sponsor
- Rempex Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of vaborbactam in complicated urinary tract infection (cUTI), acute pyelonephritis, hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), Bacteremia, sponsored by Rempex Pharmaceuticals. Started Jul 2014; status: completed.
02
Drugs
vaborbactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritishospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)Bacteremia
Beyond the preview
Go deeper on NCT02168946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168946.